AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9004107
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg and placebo
Trial: 9004107
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg and indomethacin
Trial: 26037274
Drug: 30% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% silver diammine fluoride (SDF) solution applied every 12 months
Trial: 26037274
Drug: 30% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% silver diammine fluoride (SDF) solution applied three times at weekly intervals at baseline
Trial: 26037274
Drug: 5% sodium
RxNorm normalized name: Dextrose 5% and 0.45% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% sodium fluoride (NaF) varnish applied three times at weekly intervals at baseline
Trial: 17586783
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 or 20 mg per day)
Trial: 12127180
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment of insomnia
Trial: 12127180
Drug: SDB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDB treatment (either nasal CPAP or nasal turbinates)
Trial: 12127180
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment of insomnia (10 sleep hygiene recommendations)
Trial: 12127180
Drug: SDB treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDB treatment (nasal CPAP or nasal turbinates)
Trial: 8569816
Drug: Flutrimazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutrimazole 1% solution, applied once daily for 4 weeks
Trial: 8569816
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% solution, applied once daily for 4 weeks
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 0.5 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 1 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 2 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 4 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 5 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 8 mg/hr
Trial: 2357865
Drug: Nicardipine hydrochloride
RxNorm normalized name: Nicardipine Hydrochloride
DrugBank: Nicardipine (DB00622)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicardipine hydrochloride 2 mg/hr (severe hypertension)
Trial: 6274571
Drug: Sham infusions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham infusions
Trial: 6274571
Drug: Hydrocortisone infusions
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone infusions
Trial: 6274571
Drug: Propranolol or
RxNorm normalized name: propranolol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol or indomethacin (additional treatment)
Trial: 29251954
Drug: Internet-based affect-focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based affect-focused psychodynamic therapy (IPDT) for 10 weeks
Trial: 27454410
Drug: Manualized Integrated
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manualized Integrated Mood Management (MIMM); self-administered psychoeducation.
Trial: 22467107
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration (16 IU)
Trial: 10390212
Drug: Zanamivir (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanamivir (600 mg) intravenously twice daily for 5 days
Trial: 6365208
Drug: PF therapy
RxNorm normalized name: PF-05180999
DrugBank: PF-05180999 (DB14885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF therapy (1-phenylalanine mustard and 5-fluorouracil)
Trial: 28114735
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg oral single dose) with glibenclamide (5 mg) and metformin (500 mg)
Trial: 28114735
Drug: Carvedilol (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25 mg oral single dose) in type 2 diabetes mellitus patients
Trial: 26114297
Drug: Universal vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal vaccination with one dose of 23-valent pneumococcal polysaccharide vaccine (PPV23)
Trial: 23052228
Drug: zoledronate 5
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: zoledronate 5 mg
Trial: 20497640
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) + inhaled corticosteroids (ICS)
Trial: 20497640
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) alone
Trial: 8905424
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 72 mg/kg i.v. as a bolus, later 72 mg/kg over 12 h
Trial: 1867454
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 50, 200, or 800 micrograms twice daily for 4 weeks
Trial: 6347382
Drug: Clotrimazole (1%)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole (1%) vaginal cream for seven days
Trial: 6347382
Drug: Miconazole (2%)
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole (2%) vaginal cream for seven days
Trial: 6347382
Drug: Clotrimazole (1%)
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole (1%) vaginal cream
Trial: 6347382
Drug: Miconazole (2%)
RxNorm normalized name: Miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Miconazole (2%) vaginal cream
Trial: 31466807
Drug: Caregiving self‐management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caregiving self‐management support program (six bi‐weekly social support group sessions)
Trial: 31466807
Drug: Telephone instructions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone instructions (three monthly instructions)
Trial: 31576437
Drug: Na154 (154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na154 (154 mmol/L sodium)
Trial: 31576437
Drug: Na54 (54
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Na54 (54 mmol/L sodium)
Trial: 28372526
Drug: Adjunctive metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive metformin (n=253)
Trial: 25525759
Drug: Nanorap (topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanorap (topical application of 2 g)
Trial: 15497366
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg x kg(‐1) body mass, initial dose)
Trial: 15497366
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg x kg(‐1) body mass, re-dose)
Trial: 9083710
Drug: Famotidine (20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (20-mg wafer)
Trial: 9083710
Drug: Ranitidine (150-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150-mg tablet)
Trial: 3574641
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg twice daily for 6 days
Trial: 3574641
Drug: Ketanserin 20
RxNorm normalized name: ketanserin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 20 mg for 2 weeks followed by 40 mg for 3 weeks
Trial: 25422826
Drug: 5-mm short
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-mm short implants
Trial: 26438161
Drug: Anakinra (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anakinra (recombinant human interleukin‐1 receptor antagonist)
Trial: 26392328
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg alone
Trial: 22946890
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg with verapamil 120 mg immediate release given 1 hour before DE
Trial: 22946890
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg with verapamil 240 mg extended release
Trial: 22946890
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg after multiple verapamil dosing
Trial: 22946890
Drug: Dabigatran etexilate
RxNorm normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dabigatran etexilate (DE) 150 mg given 2 hours before verapamil
Trial: 21455785
Drug: Low-Intensity Laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Intensity Laser Therapy (LILT) using combined He-Ne and infrared lasers
Trial: 19555315
Drug: Silymarin (140
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin (140 mg capsules, three times daily for 14 days)
Trial: 15167084
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate (MPH) 0.60 mg/kg b.i.d.
Trial: 11475920
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mgs/day)
Trial: 2167452
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (500 mg/kg weekly to day 90, then monthly to day 360 after transplantation)
Trial: 30149825
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy - Long (CBT-L)
Trial: 30149825
Drug: Cognitive Behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behaviour Therapy - Brief (CBT-B)
Trial: 25187694
Drug: Intravitreal pegaptanib
RxNorm normalized name: pegaptanib
DrugBank: Pegaptanib (DB04895)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal pegaptanib 0.3 mg
Trial: 20714187
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab 1.25 mg
Trial: 21210134
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hCG (100 IU/day) with reduced r‐FSH (75 IU) after lead follicle reached 14 mm
Trial: 21210134
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose hCG (200 IU/day) with discontinued r‐FSH after lead follicle reached 14 mm
Trial: 19788471
Drug: Frovatriptan (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frovatriptan (twice daily)
Trial: 16499880
Drug: ABT-089 2
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-089 2 mg b.i.d.
Trial: 16499880
Drug: ABT-089 4
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-089 4 mg b.i.d.
Trial: 16499880
Drug: ABT-089 20
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-089 20 mg b.i.d.
Trial: 9025426
Drug: Sequential single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential single electric breast pumping system
Trial: 6835893
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg meptazinol
Trial: 6835893
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg meptazinol
Trial: 6835893
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg meptazinol
Trial: 6835893
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of meptazinol
Trial: 3514702
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% cream for 1 week
Trial: 3514702
Drug: Bifonazole 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bifonazole 1% cream for 2 weeks
Trial: 25541827
Drug: Sausalin at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sausalin at a dose of 720 mg/day
Trial: 25541827
Drug: Ornidazole at
RxNorm normalized name: ornidazole
DrugBank: Ornidazole (DB13026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornidazole at a dose of 1500 mg/day
Trial: 20597951
Drug: Nicotinamide gel
DrugBank: Nicotinamide (DB02701)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotinamide gel 4%
Trial: 12942871
Drug: Fermented soy
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fermented soy milk (200 ml daily)
Trial: 12942871
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 ml chemically fermented)
Trial: 1354086
Drug: Epanolol, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epanolol, 200 mg o.d.
Trial: 1354086
Drug: Atenolol, 100
RxNorm normalized name: Atenolol, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol, 100 mg o.d.
Trial: 30616140
Drug: Low-charge electrotherapy
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-charge electrotherapy (LCE), administered three times a week, approximately 2.8 Joules
Trial: 27412415
Drug: BCG revaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG revaccination after isoniazid preventive therapy (IPT)
Trial: 6147551
Drug: Zinc acetate
RxNorm normalized name: Zinc Acetate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc acetate 600 mg a day for 7 days
Trial: 24672331
Drug: Intensive atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive atorvastatin group (I‐A group)
Trial: 23290037
Drug: Roxithromycin disperse
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin disperse tablet 0.15 g every day and ambroxol hydrochloride tablet 90 mg 3 times a day
Trial: 23290037
Drug: Ambroxol hydrochloride
RxNorm normalized name: AMBROXOL HYDROCHLORIDE
DrugBank: Ambroxol (DB06742)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol hydrochloride tablet 90 mg 3 times a day
Trial: 15692221
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg b.i.d. for 4 days
Trial: 15692221
Drug: Ibuprofen 80
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 80 mg b.i.d. for 4 days
Trial: 10423311
Drug: Aerosolized ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aerosolized ribavirin high dose (6 g/100 mL over 2 hr, three times a day)
Trial: 10423311
Drug: Aerosolized ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Aerosolized ribavirin regular dose (6 g/300 mL over 18 hr/day)
Trial: 7557855
Drug: Interferon alfa
RxNorm normalized name: Interferon alfa
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa 3 mIU three times weekly for 6 months
Trial: 2164528
Drug: Enalapril (E)
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril (E) 10 mg orally
Trial: 30738995
Drug: Moderate alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moderate alcohol consumption (<10 g/day)
Trial: 28088839
Drug: TAK-648 (PDE4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-648 (PDE4 inhibitor) at doses of 0.05-0.85 mg in healthy volunteers
Trial: 28088839
Drug: TAK-648 (PDE4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-648 (PDE4 inhibitor) at a daily dose of 0.1 mg
Trial: 25636072
Drug: Ivabradine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivabradine (10 mg twice a day for 6 weeks)
Trial: 25636072
Drug: Metoprolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (100 mg twice a day for 6 weeks)
Trial: 18469148
Drug: Nitro-l-arginine (NLA)
RxNorm normalized name: Ngamma-Nitro-L-arginine
DrugBank: Nitroarginine (DB04223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitro-l-arginine (NLA)
Trial: 16950434
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (SEPS combined with superficial vein ligation)
Trial: 16950434
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (ambulatory compression therapy)
Trial: 2498620
Drug: Kliogest (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kliogest (continuous treatment)
Trial: 2498620
Drug: Trisequens (sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trisequens (sequential treatment)
Trial: 1091856
Drug: Intermittent intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intravenous injection of heparin
Trial: 1091856
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of heparin
Trial: 1091856
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with laboratory control (partial thromboplastin time)
Trial: 1091856
Drug: Heparin without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin without laboratory control
Trial: 30889093
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of isoflavones (10mg, n = 35)
Trial: 30889093
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of isoflavones (35mg, n = 37)
Trial: 30889093
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of isoflavones (60mg, n = 29)
Trial: 30889093
Drug: Overall sample
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall sample (all doses)
Trial: 25953600
Drug: Novel low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel low energy-dense semi-solid food (0.72kcal/g)
Trial: 25953600
Drug: Higher energy-dense
RxNorm normalized name: Senergy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher energy-dense semi-solid food (1.57kcal/g)
Trial: 1362320
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine alone (group I)
Trial: 1362320
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine in combination with HBIG (group II)
Trial: 3932033
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy of prednisone, azathioprine, cyclophosphamide, Heparoid Spofa forte ling., Heparin retard Spofa and dipyridamole
Trial: 29654643
Drug: Sitagliptin 0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 0 mg (placebo)
Trial: 27068582
Drug: Postoperative patient-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative patient-controlled intravenous analgesia
Trial: 24304349
Drug: 3 months
RxNorm normalized name: TABLET, DOSE PACK, 3 MONTHS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 months of daily supervised consumption of OMT
Trial: 24304349
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month or less of daily supervised OMT, then daily unsupervised consumption
Trial: 24304349
Drug: 1 month
RxNorm normalized name: LUPRON-PED 15MG (1 MONTH) SA INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 month or less of daily unsupervised consumption
Trial: 15253170
Drug: Transdermal therapeutic
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal therapeutic system fentanyl (TTS-F)